• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

质谱细胞术揭示了多发性骨髓瘤亚克隆多样性及结果相关的独特表型模式。

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.

机构信息

Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2023 May 22;13(1):84. doi: 10.1038/s41408-023-00851-5.

DOI:10.1038/s41408-023-00851-5
PMID:37217482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10203138/
Abstract

Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. Although it is known that MM tumor cells display extensive intratumoral genetic heterogeneity, an integrated map of the tumor proteomic landscape has not been comprehensively evaluated. We evaluated 49 primary tumor samples from newly diagnosed or relapsed/refractory MM patients by mass cytometry (CyTOF) using 34 antibody targets to characterize the integrated landscape of single-cell cell surface and intracellular signaling proteins. We identified 13 phenotypic meta-clusters across all samples. The abundance of each phenotypic meta-cluster was compared to patient age, sex, treatment response, tumor genetic abnormalities and overall survival. Relative abundance of several of these phenotypic meta-clusters were associated with disease subtypes and clinical behavior. Increased abundance of phenotypic meta-cluster 1, characterized by elevated CD45 and reduced BCL-2 expression, was significantly associated with a favorable treatment response and improved overall survival independent of tumor genetic abnormalities or patient demographic variables. We validated this association using an unrelated gene expression dataset. This study represents the first, large-scale, single-cell protein atlas of primary MM tumors and demonstrates that subclonal protein profiling may be an important determinant of clinical behavior and outcome.

摘要

多发性骨髓瘤(MM)仍然是一种无法治愈的浆细胞瘤(PC)恶性肿瘤。虽然已知 MM 肿瘤细胞显示出广泛的肿瘤内遗传异质性,但肿瘤蛋白质组景观的综合图谱尚未得到全面评估。我们通过质谱流式细胞术(CyTOF)使用 34 种抗体靶标对 49 个新诊断或复发/难治性 MM 患者的原发性肿瘤样本进行了评估,以表征单细胞表面和细胞内信号蛋白的综合景观。我们在所有样本中鉴定了 13 个表型元簇。将每个表型元簇的丰度与患者年龄、性别、治疗反应、肿瘤遗传异常和总生存期进行了比较。这些表型元簇中的几个的相对丰度与疾病亚型和临床行为有关。表型元簇 1 的丰度增加,其特征是 CD45 升高和 BCL-2 表达降低,与治疗反应良好和总生存期改善独立于肿瘤遗传异常或患者人口统计学变量显著相关。我们使用一个不相关的基因表达数据集验证了这种关联。这项研究代表了原发性 MM 肿瘤的第一个大规模单细胞蛋白质图谱,表明亚克隆蛋白谱可能是临床行为和结果的重要决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/2d31b738c845/41408_2023_851_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/d76365dc08ea/41408_2023_851_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/06bcb36f5a09/41408_2023_851_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/521d025c2398/41408_2023_851_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/2d31b738c845/41408_2023_851_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/d76365dc08ea/41408_2023_851_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/06bcb36f5a09/41408_2023_851_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/521d025c2398/41408_2023_851_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51c3/10203138/2d31b738c845/41408_2023_851_Fig4_HTML.jpg

相似文献

1
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.质谱细胞术揭示了多发性骨髓瘤亚克隆多样性及结果相关的独特表型模式。
Blood Cancer J. 2023 May 22;13(1):84. doi: 10.1038/s41408-023-00851-5.
2
Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome.对多发性骨髓瘤患者的恶性浆细胞进行同时的脂质组学和蛋白质组学研究:探索脂质代谢组。
PLoS One. 2020 Jan 8;15(1):e0227455. doi: 10.1371/journal.pone.0227455. eCollection 2020.
3
A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.浆细胞恶性肿瘤的转基因小鼠模型表现出与人类多发性骨髓瘤相似的表型、细胞遗传学和基因表达异质性。
Cancer Res. 2007 May 1;67(9):4069-78. doi: 10.1158/0008-5472.CAN-06-3699.
4
Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.无富集的骨髓瘤患者样本单细胞检测与类器官基因分析以描绘循环稀有浆细胞克隆。
Curr Oncol. 2022 Apr 21;29(5):2954-2972. doi: 10.3390/curroncol29050242.
5
Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.中泰两国浆细胞疾病的临床特征和遗传学异常比较。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221111228. doi: 10.1177/15330338221111228.
6
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.表面分子 CD229 作为多发性骨髓瘤诊断和治疗的新靶点。
Haematologica. 2011 Oct;96(10):1512-20. doi: 10.3324/haematol.2010.036814. Epub 2011 May 23.
7
The oncoprotein phenotype of plasma cells from patients with multiple myeloma.多发性骨髓瘤患者浆细胞的癌蛋白表型。
Leuk Lymphoma. 1994 Dec;16(1-2):147-56. doi: 10.3109/10428199409114152.
8
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.初治多发性骨髓瘤患者浆细胞的蛋白质组学分析确定了与基于硼替佐米治疗方案的良好反应相关的途径。
Br J Haematol. 2015 Jul;170(1):66-79. doi: 10.1111/bjh.13394. Epub 2015 Mar 30.
9
Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma.血清蛋白质组学分析显示 MTA2 和 AGO2 可能是多发性骨髓瘤疾病活动和不良预后相关的潜在预后生物标志物。
PLoS One. 2022 Dec 1;17(12):e0278464. doi: 10.1371/journal.pone.0278464. eCollection 2022.
10
Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.肿瘤性浆细胞对罗丹明123的外排与多发性骨髓瘤临床和生物学特征的相关性
Cytometry. 1999 Feb 15;38(1):24-9.

引用本文的文献

1
Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.意义未明的单克隆丙种球蛋白血症进展为多发性骨髓瘤与翻译质量控制增强和表面抗原整体丢失有关。
J Transl Med. 2024 Jun 7;22(1):548. doi: 10.1186/s12967-024-05345-x.
2
Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.利用基于蛋白质的方法对人类 B 细胞血液系统恶性肿瘤进行表征。
Int J Mol Sci. 2024 Apr 24;25(9):4644. doi: 10.3390/ijms25094644.
3
Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation.

本文引用的文献

1
Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing.通过纵向单细胞转录组测序鉴定多发性骨髓瘤中的药物反应基因
iScience. 2022 Jul 19;25(8):104781. doi: 10.1016/j.isci.2022.104781. eCollection 2022 Aug 19.
2
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.多发性骨髓瘤细胞的表面组学提示了潜在的免疫治疗策略和耐药性的蛋白标志物。
Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6.
3
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma.
多组学研究对多发性骨髓瘤起始、演变和进展的新见解
Cancers (Basel). 2024 Jan 24;16(3):498. doi: 10.3390/cancers16030498.
重新定义 CD56 在多发性骨髓瘤中的生物标志物和治疗靶点。
Mol Cancer Res. 2022 Jul 6;20(7):1083-1095. doi: 10.1158/1541-7786.MCR-21-0828.
4
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.单细胞 RNA 测序揭示复发多发性骨髓瘤的克隆多样性和预后基因。
Clin Transl Med. 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757.
5
Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.在单细胞分辨率下解析多发性骨髓瘤中的空间基因组异质性。
Nat Commun. 2022 Feb 10;13(1):807. doi: 10.1038/s41467-022-28266-z.
6
Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.使用质谱法追踪达雷妥尤单抗的清除率:对M蛋白监测及达雷妥尤单抗再利用的影响
Leukemia. 2022 May;36(5):1426-1428. doi: 10.1038/s41375-021-01501-0. Epub 2022 Jan 29.
7
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States.新型疗法在美国问世后多发性骨髓瘤的死亡率趋势。
Leukemia. 2022 Mar;36(3):801-808. doi: 10.1038/s41375-021-01453-5. Epub 2021 Oct 26.
8
Co-evolution of tumor and immune cells during progression of multiple myeloma.多发性骨髓瘤进展过程中肿瘤细胞与免疫细胞的协同进化。
Nat Commun. 2021 May 7;12(1):2559. doi: 10.1038/s41467-021-22804-x.
9
Positive selection as the unifying force for clonal evolution in multiple myeloma.正向选择作为多发性骨髓瘤克隆进化的统一驱动力。
Leukemia. 2021 May;35(5):1511-1515. doi: 10.1038/s41375-021-01130-7. Epub 2021 Jan 22.
10
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.